Patients with vitiligo vulgaris are treated with Pimecrolimus twice a day during 6 months. After a baseline visit, patient returns for a control visit after 3 and 6 months of treatment. One reference lesion is clinically evaluated with pictures.

Inclusion Criteria:

• Active or stable vitiligo vulgaris
• lesions at head or neck + maximum 10% lesions at the rest of the body

Exclusion Criteria:

• Topica during last 2 weeks
• Photo(chemo)therapy during last 4 weeks
• Segmentary vitiligo